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Brain metastases represent an important cause of morbidity in patients with lung cancer and are associated with a mean survival of
less than 6 months. Thus, new regimens improving the outcome of these patients are urgently needed. On the basis of promising data
raised in a phase I/II trial, we initiated an open, randomised, prospective, multicentric phase III trial, comparing whole brain radiation
therapy (WBRT; 20 2Gy) alone with WBRTþtopotecan (RCT; 0.4mgm
 2day
 1 20). A total of 320 patients with CNS-
metastases due to SCLC or NSCLC were projected. The primary end point was overall survival, whereas second end points were
local response and progression-free survival. However, until the cutoff date of study completion (i.e., a study duration of 34 months),
only a total of 96 (RCT:47, WBRT:49) patients had been recruited, and so an analysis was performed at that time point. Although the
numbers of grade 3/4 non-haematological toxicities (besides alopecia 115 (RCT/WBRT: 55 out of 60) were evenly distributed, the
25 haematological events occurred mainly in the combined treatment arm (24 out of 1). Local response, evaluated 2 weeks after
treatment, was assessable in 44 (RCT/WBRT: 23 out of 21) patients, showing CR in eight (3 out of 5), PR in 17 (11 out of 6), SD in
14 (8 out of 6) and PD in five (1 out of 4) patients (all differences n.s.). Neither OAS (RCT/WBRT: median (days)): 87 out of 95,
range 3–752/4–433; HR 1.32; 95% CI (0.83; 2.10)) nor PFS (median (days)): 71 out of 66, range, 3–399/4–228; HR 1.28, 95% CI
(0.73; 2.43) differed significantly. On the basis of these results and the slow recruitment, a continuation of the study did not seem
reasonable. The available data show no significant advantage for concurrent radiochemotherapy for patients with lung cancer;
however, the recruited number of patients is too low to exhibit a small advantage of combined treatment.
British Journal of Cancer (2009) 100, 291–297. doi:10.1038/sj.bjc.6604835 www.bjcancer.com
Published online 6 January 2009
& 2009 Cancer Research UK
Keywords: brain metastases; lung cancer; radiochemotherapy; topotecan
                                                         
Brain metastases represent an important cause of morbidity in
patients with solid tumours. Most often, they were found
in cancers of the lung with incidences in autoptic series of 54%
in NSCLC and 80% in SCLC (Riva et al, 2001), and these tumour
types account for more than one half of all brain metastases (Zimm
et al, 1981).
Besides the local neurological complications, the occurrence of
brain metastases is also a sign of systemic failure of tumour
control, going ahead with a median survival time in untreated
patients of about 1 month (Sundstrom et al, 1998). Thus, the
treatment of brain metastases should focus on both, the control of
neurological symptoms as well as a prolonged survival rate.
Although in patients with a limited number of CNS-metastases,
surgery or stereotactic radiosurgery represents important ther-
apeutic approaches (Patchell et al, 1990; Andrews et al, 2004;
Jawahar et al, 2004), in those patients with multiple CNS-
metastases, Whole Brain Radiotherapy (WBRT) is still the
treatment of choice. A reduction of neurological complications is
mostly achieved however, it results only in an overall survival
benefit of approximately 4 months (Lagerwaard et al, 1999;
Postmus, 1995; Saito et al, 2006), and a control of brain metastases
will be found in only 50% of the patients (Lassman and DeAngelis,
2003).
As an alternative, the efficacy of chemotherapy in the treatment
of brain metastases has been investigated. However, the response
rates found in the treatment of brain metastases in mainly non-
randomised studies were about 20–40% with a median survival
time varying from 3 to 10 months and have thus been
disappointing (Nieder et al, 2006).
Therefore, an improvement of these results is urgently needed.
One approach was the addition of radiosensitisers to WBRT.
However, the few studies on this subject published to date failed to
show any significant effect on overall survival or on local response
rate (Tsao et al, 2006).
For multimodal treatment strategies, including combination of
chemotherapy (e.g., temozolomide, paclitaxel, nimustine, tegafur)
with WBRT, sufficient data are rare, too. Although most of
the studies pointed out an improvement in local control
compared with WBRT, the median survival times did not differ
(Postmus et al, 2000; Robinet et al, 2001; Ushio et al, 1991
Mornex et al, 2003).
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sA promising candidate for a combined radiochemotherapy
seems to be topotecan, a topoisomerase I inhibitor with a well
established activity in the systemic treatment of SCLC (von Pawel
et al, 1999) and NSCLC (Stewart, 2004), a high brain capillary
permeability (Sung et al, 1994; Baker et al, 1996) and radio-
sensitising effects (Kim et al, 1992; Lamond et al, 1996). For
topotecan in a monotherapeutic setting, response rates of 33–63%
in patients with brain metastases due to SCLC were found
(Ardizzoni et al, 1997; Schutte et al, 1999; Korfel et al, 2002;
summarised in Wong and Berkenblit, 2004).
As a consequence, three phase I/II-studies were initiated to
evaluate the feasibility of topotecan-based combined radiochemo-
therapy in patients with brain metastases (Gruschow et al, 2002;
Kocher et al, 2005; Hedde et al, 2007). In the setting of the dose-
escalating phase I studies, Gruschow et al (2002) and Hedde et al
(2007) found tolerable toxicities in those patients receiving
0.4mgm
 2day
 1 topotecan, either as a bolus or continuous
infusion, concurrent with the WBRT (fraction size of 2Gyday
 1
for a total of 40Gy). Kocher et al (2005) used a regimen with local
target dosage of 36Gy in 3-Gy-fractions and topotecan adminis-
tered 12 0.5mgm
 2day
 1.
In the study published by Hedde et al (2007) 19% of their 68
patients developed grade 3/4 haematological and 21% developed
grade 3/4 non-haematological events. Of their 47 patients, in whom
a local response was assessable, seven presented with complete and
27 with partial responses (i.e. an overall response rate of 72%). The
median survival of all patients reached 17 weeks and amounted to
33 weeks in responders.
Gruschow et al (2002) included 20 patients and found a median
survival of 5 months. In 13 patients, the remission status could be
evaluated; four complete and two partial responders were detected,
resulting in an overall response rate of 46%.
Of the 47 patients who took part in the study of Kocher et al
(2005), response evaluation was possible in 26 patients. In them, an
overall response rate of 58% was described (5 out of 26 complete
response (CR) and 10 out of 26 partial response (PR)). Grade 3/4
haematological toxicities were found in 25% of all patients.
On the basis of these promising results, we initiated a phase III
study comparing the efficacy of a combined radiochemotherapy
with topotecan and WBRT vs WBRT alone in patients with brain
metastases from lung cancer.
PATIENTS AND METHODS
Patient eligibility
Patients with histologically proven lung cancer and intracerebral
metastases have been entered in this open-label, prospective,
multicentric, randomised phase III study. Initially only patients
with recurrence of lung cancer after first line therapy could be
included in the study. However, due to a slow recruitment, after 1
year an amendment allowing the inclusion of primary diagnosed
patients was added. Patients were enrolled with ages between 18–
75 years, and at least one measurable lesion in the brain was
confirmed by computed tomography (CT) or magnetic resonance
imaging. Sufficient bone marrow reserve was defined as neutrophil
counts X1500ml
 1, leukocyte counts X3500ml
 1, platelet counts
X100000ml
 1 and haemoglobin X9gdl
 1. Adequate renal func-
tion was defined by serum creatinine concentration p1.5mg% or
creatinine clearance 460mlmin
 1. Patients had to have a
performance status of 0–2 according to ECOG criteria.
Exclusion criteria were prior to cerebral radiotherapy and/or
surgery of cerebral metastases (except stereotactic biopsy), missing
histologically proven nature of cancer, solitary intracerebral
metastases suitable for neurosurgery, meningeosis carcinomatosa,
active uncontrolled infection, concomitant or previous malignan-
cies, except basal or squamous cell carcinoma or carcinoma in situ
of the cervix and history of therapy with and/or known allergy to
topoisomerase I inhibitors, pregnant or breast-feeding women. All
patients were informed of the investigational nature of the study
and had to provide written informed consent. The study was
approved by local ethics committees of all participating centres.
Randomisation was performed by considering the parameters
SCLC, NSCLC, extracerebral metastases and a number of brain
metastases.
Treatment protocol
Arm A (radiochemotherapy): Topotecan was administered as a
30min infusion with 0.4mgm
 2day
 1 for 5 days over 4 weeks
within 2h before radiation therapy. Whole Brain Radiation (WBR)
was applied with a fraction size of 2Gyday
 1 to a total of 40Gy.
Arm B (Radiotherapy): WBR was applied with a fraction size of
2Gyday
 1 to a total of 40Gy.
Continuation therapy: subsequently, patients with extracerebral
cancer lesions from both arms had the option to receive three
additional cycles of topotecan chemotherapy (1.25mgm
 2day
 1,
d1–5, q21d), starting on day 15 after the end of WBRT. In case a
patient had not received any kind of chemo- or radiochemother-
apy before entering the study, the institutionally preferred
chemotherapeutic regimen was allowed to be used instead
Continuation therapy was stopped after three cycles or when
tumour progression of the extracerebral metastases occurred.
Dose delays and modifications
In the case of severe neutropenia (neutrophil counts p1000ml
 1)
or thrombocytopenia (platelet counts p50000ml
 1), topotecan
therapy was stopped until recovery of neutrophil counts to
X15000ml
 1 and of platelet counts to X100000ml
 1. Radiation
therapy was continued as planned. Therapeutic use of G-CSF was
allowed and left to the decision of the treating physician.
Antiemetic and supportive symptom treatment was left to the
treating physician as well. For dexamethasone, a dosage of 4mg
two times per day was recommended; the dosage should not
exceed 12mgday
 1. During the continuation therapy, a dose
reduction of 0.25mgm
 2day
 1 topotecan for the next cycle was
recommended in the case of thrombocytopenia (platelet counts
p50000ml
 1), whereas in the case of neutropenia, G-CSF should
be applicated without reduction of the topotecan dosage. Again,
therapy was continued after neutrophil counts increased to
X15000ml
 1 and platelet counts to X100000ml
 1.
Withdrawal from the study
The treatment was stopped as per the patients’ wish, by the
decision of the physician, tumour progression, severe side effects
according to the NCIC CTCG guidelines or non-compliance of the
patient. The whole study was to be stopped in case new therapeutic
regimens with superior benefit of either therapy arm were
published, if the interim analyses showed that the criteria for
stopping the study by using the methods of Pocock (1978) and
O’Brien and Fleming (1979) were reached and when the number of
patients recruited was clearly below the expected value.
Tumour assessment
Criteria for efficacy assessment were response rate, progression-
free survival and overall survival. A complete response was defined
as a complete disappearance of all evidence of disease in the brain.
A partial response was defined as radiological response 450% in
all brain metastases. Responses in tumour lesions o50% or
increase in size less than 25% was defined as stable disease. A
progressive disease was defined as either the occurrence of new
lesions or an increase in size of more than 25%. Tumour
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sassessment was performed with the method used initially. In
addition, death caused by cerebral lesions was assessed if one of
the following causes of death were described: Cerebral oedema,
neurologic disorders, cramps, dementia and progression of
cerebral lesions.
Tumour assessment was also performed for extracerebral
lesions. Assessment of brain metastases by imaging was performed
on day 15 after the end of radiotherapy/radiochemotherapy; in the
case of a complete remission, it was repeated 4 weeks later. The
final examination was planned for week 17 for patients with
extracerebral tumours, and it included extracranial tumour
imaging.
Safety assessment
Baseline evaluations included medical history, physical examina-
tion, radiologic assessment of tumour status by cerebral CT or MR,
conventional X-ray or CT of the lung and CT of the upper
abdomen, ECOG scale, and laboratory evaluations. Full blood
counts and biochemistry were measured weekly. On week 7 (15
days after end of the treatment), the following assessments were
performed: physical examination, documentation of side effects,
cerebral tumour status, neurologic status, blood counts and blood
chemistry. During the continuation therapy full blood counts and
biochemistry were measured before each course, and side effects
were documented. On week 17, the final examination for all
patients included physical examination, extracranial tumour
imaging in the case of extracerebral tumours, neurologic status,
laboratory evaluations and documentation of palliative treatment.
During follow-up visits, the toxicities and palliative treatments
were documented every 8 weeks.
Quality of life
For recording the quality of life we used the EORTC-QLQ C30A
questionnaire added by the brain cancer module EORTC-QLQ BN20.
The patients should get these questionnaires before treatment, 2 weeks
after treatment and at follow-up. However, an analysis was not possible
owing to the very low number of returned questionnaires.
Statistical considerations
The primary end point was overall survival (OAS). Secondary end
points were progression-free survival, rates of complete responses
of the cerebral lesions, duration of remission, status of the
extracerebral tumours after continuation therapy and toxicity.
As mentioned, the primary end point with regard to therapeutic
efficacy is the survival time of the patients starting at the
randomisation time point. Event is the time of death. The sample
size estimate for the study was based on a sequential study design
with two samples and an interim analysis. The reference value was
the median survival time of 4 months under standard therapy
(radiotherapy, Arm B). The estimated minimum clinically relevant
therapeutic effect under investigational treatment (radioche-
motherapy, Arm A) was an increase in the survival time in the
interventional group to 5.5 months. The study protocol justifies
the one-sided testing by the fact that a longer survival time in
patients under the investigational therapy can be assumed to be
highly likely. For the testing of this study design, the estimated
number of patients was 320 (i.e., 160 patients per treatment arm
with equal distribution). Dropouts were not considered.
An interim analysis was planned after the death of the first 150
patients (event of primary end point); the decision concerning the
continuation of the study was based on using the a-spending
principle with criteria for closing the study described by Pocock
(1978) and O’Brien and Fleming, (1979).
Overall survival was defined as the interval from randomisation
until death. Progression-free survival was defined as the interval
from randomisation until evidence of disease progression or death.
Analysis was performed by the Kaplan–Meier estimation. Overall
survival and progression-free survival were compared using the
log-rank test. Regression analyses were performed by using the
Cox proportional hazards model. The analyses of all other
secondary end points were evaluated in an explorative or
descriptive manner.
RESULTS
Patient characteristics
The first patient was included in October 2001. An interim analysis
was planned after the death of 150 patients. However, until August
6, 2004, that is, after a study duration of 34 months, only 95
patients in 11 centres had been recruited, and so the interim
analysis was performed at that time point. This analysis did not
show any benefit of radiochemotherapy with regard to overall
survival and thus, on the basis of the slow recruitment and the
result of the interim analysis, a continuation of the study did no
longer appear reasonable. The results described here represent the
final analysis, in which 96 patients were included.
The demographic data as presented in Table 1 were evenly
distributed in the two groups. Most of the patients (64%) had a
good ECOG performance status of 0–1, and 75% of the patients
had extracerebral metastases. There were 25 patients (26%) with
more than four CNS-metastases, and 15.6% of the patients received
continuation therapy with topotecan.
Table 1 Demographic results
Radiochemotherapy Radiotherapy
No. of patients 47 49
Age
Median 58 59
Range 34–75 42–75
Male/female 32/15 30/19
Primary site of tumour
NSCLC first line 7 8
NSCLC recurrence 24 24
SCLC first line 3 2
SCLC recurrence 13 15
ECOG performance status
08 2
12 9 2 2
27 1 9
31 2
Not reported 2 4
No. of brain metastases 44
Yes 11 14
No 36 35
Extracerebral metastases
Yes 35 37
No 12 12
Dexamethasone dosing
Yes 38 39
Not 9 8
Not reported 0 2
Courses of continuation therapy
11 2
21 1
36 4
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Only half of the patients (51%) were reported to be treated
per protocol, whereas 49% of the patients were not. The
reasons for protocol deviations are mainly early deaths, haemato-
logical toxicities, dosage failure, worsening of general
condition and tumour progression. In detail, in arm A the
chemotherapy was delayed or reduced in nine patients because
of neutropenia, and in six of them G-CSF was given at
least once. Although no patient stopped topotecan because of
neutropenia, one patient left the study because of prolonged
thrombocytopenia.
The main cause of early death (Table 2), defined as death within
6 weeks after recruitment, was tumour progression. Early death
occurred in 24% of the patients, and of these 61% belonged to the
arm receiving radiochemotherapy. The main causes of death in
general were tumour progression, especially in 18 patients’ (3 arm
A, 15 arm B) progression of cerebral lesions.
The occurrence of non-haematological grade 3/4 toxicities did
not differ between both treatment arms (Table 3). In total, besides
alopecia found in about 40% of all patients, 118 non-haematotoxic
grade 3/4 adverse events were described. Haematological toxicities
occurred – as expected – more often in the radiochemotherapy
arm (Table 3). All in all, 25 grade 3/4 haematotoxic adverse events
were reported, 24 in the patients receiving the combined approach
and one in the patient treated with WBRT alone.
Response
Response of brain metastases, evaluated about 2 weeks after
treatment, was assessable in 44 patients (radiochemotherapy/
radiotherapy: 23 out of 21), showing CR in eight (3 out of 5), PR in
17 (11 out of 6), stable disease (SD) in 14 (8 out of 6) and
progressive disease (PD) in five (1 out of 4) patients (Table 4). Data
concerning the response behaviour of extracerebral metastases
after continuation therapy were available in just 10 (radio-
chemotherapy/radiotherapy: 6 out of 4) patients. Although in the
patients receiving radiochemotherapy 2 PR, 1 SD and 3 PD were
found, all four patients in the radiotherapy-arm presented with PD.
Neither overall survival (radiochemotherapy/radiotherapy: median
(days): 87 out of 95, range 3–752 out of 4–433; Hazard Ratio 1.32,
95% CI 0.83–2.1) nor progression-free survival (assessable in 44
patients; median (days): 71 out of 66, range: 3–399 out of 4–228;
Hazard Ratio 1.28, 95% CI 0.73–2.43) differed significantly
between the two groups (using Cox–Mantel test; Figure 1A and
B). This was true for SCLC and NSCLC, respectively, and thus the
histology of the lung cancer did not seem to influence the response
rates.
The co-medication was not analysed in detail, but although
serum concentration of topotecan could be diminished in
patients treated with inducers of CYP450-enzymes, the investigators
negotiated any relevant influence of these inducers on the results
of the study.
Table 2 Causes of early death (death within 6 weeks after recruitment)
Radiochemotherapy Radiotherapy
Early death 14/47 9/49
Tumour progression 7 6
Cardiovascular failure 2 0
Pulmonary embolism 1 1
Infection 2 1
GI-haemorrhage 2 0
Unknown 0 1
Table 3 Incidence of the main grade 3 and 4 adverse events (by patients)
Radiochemotherapy Radiotherapy
Grade 3 Grade 4 Grade 3 Grade 4
CTC-Grade
No.of
patients
Percentage
of patients
No.of
patients
Percentage
of patients
No.of
patients
Percentage
of patients
No.of
patients
Percentage
of patients
Granulocytes 1 2.1 3 6.4 1 2.0 0 0.0
Haemoglobin 2 4.3 0 0.0 0 0.0 0 0.0
Leukocytes 5 10.6 2 4.3 0 0.0 0 0.0
Thrombocytes 8 17.1 3 6.4 0 0.0 0 0.0
Alopecia 20 42.6 0 0.0 19 38.8 0 0.0
Infection 8 17.0 4 8.5 5 10.2 1 2.0
Somnolence 2 4.3 0 0.0 3 6.1 0 0.0
Dyspnea 4 8.5 1 2.1 0 0.0 1 2.0
Nausea 4 8.5 0 0.0 3 6.1 0 0.0
Vomiting 1 2.1 0 0.0 0 0.0 0 0.0
Constipation 3 6.4 2 4.3 3 6.1 0 0.0
Pain 5 10.6 2 4.3 7 14.3 5 10.2
Stomatitis 3 6.4 0 0.0 5 10.2 1 2.0
Hyperglycaemia 2 4.3 0 0.0 1 2.0 0 0.0
GI-haemorrhage 1 2.1 0 0.0 1 2.0 0 0.0
Sensorium 2 4.3 1 2.1 1 2.0 0 0.0
Creatinin-elevated 2 4.3 0 0.0 3 6.1 0 0.0
Pneumonitis 0 0.0 1 2.1 3 6.1 0 0.0
Table 4 Response of brain metastases
Radiochemotherapy Radiotherapy
47 49
Complete response (CR) 3 5
Partial response (PR) 11 6
Stable disease (SD) 8 6
Progressive disease (PD) 1 4
Not specified 2 3
Not assessable 22 25
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sDISCUSSION
The main goal of the presented study was to elucidate the
relevance of concurrent radiochemotherapy with topotecan
(0.4mgm
 2day
 1 for 5 days over 4 weeks) and WBRT (2Gyday
 1,
40Gy in total) in patients with brain metastases due to lung
cancer in comparison with WBRT alone concerning overall
survival. We have chosen a schedule of a 2-Gy fraction because
we wanted to use the radiosensitising effect of topotecan;
thus, both WBRT and chemotherapy should be administered
at the same time and over the same period. Second, there are no
data concerning higher doses of radiotherapy together with
topotecan; the toxicity may increase in an uncalculated manner
when 4 or 5Gy are used. On the other hand, a treatment course of
4 weeks is a long period for patients with a short life expectancy, as
is true in patients with brain metastases. Thus, a shortened
schedule would be more attractive for both patients and
physicians, and this should be kept in mind when planning
such trials.
To test this hypothesis, 320 patients needed to be enrolled. The
expected recruitment period lasted 36 months. However, after 34
months, just 96 patients could be included in the study. At this
time, an interim analysis was performed that led to the results
described above. The low recruitment was mainly caused by
patients with a limited number of cerebral metastases and by the
resulting opportunity of a local treatment (surgery or stereotactic
radiosurgery). As the recruitment rates differed to a greater
amount between the different centres, we assume that in addition
some centres overestimated the numbers of patients they were able
to include. The data presented here once again show the difficulties
in estimating the numbers of patients that may be included in each
centre, especially in trials with a wide range of exclusion criteria.
To avoid such problems, either the number of participating centres
should be enlarged or the centres chosen must meet certain
requirements.
In the study presented here, the overall response rate in the
patients receiving radiochemotherapy was 60%, whereas it was
52% in the WBRT arm. Compared with our own previous data
generated in a phase I/II study, where we found overall response
rates of 72% (Hedde et al, 2007), the outcome of the patients
treated with a combined approach was inferior. However, our
results confirm the findings of the only two comparable studies
testing a topotecan-based radiochemotherapy, in which overall
response rates of 46 and 58%, respectively, were described
(Gruschow et al, 2002; Kocher et al, 2005).
With regard to the observed response rates, it was not surprising
that neither OAS nor PFS were increased in the combined
treatment arm. This was true independent of the kind of lung
cancer; thus, even in patients with SCLC, possibly because of the
low numbers of patients in each subgroup, we were not able to
show improved results when using the combined approach. As
lung cancer is not a homogeneous disease, further studies of such a
kind should focus on either NSCLC or SCLC to get the definite
answer that was missed here. In addition, this approach would
have the advantage of being able to choose a chemotherapy
optimal for the respective cancer.
Besides the response, another interesting point in brain
metastases is the diminished quality of life, which should be
observed and analysed in trials dealing with this disease for
answering the question whether more aggressive treatment is
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Figure 1 Overall survival (A) and progression-free survival (B) in both arms (HR¼Hazard ratio; RCT¼radiochemotherapy; RT¼radiotherapy).
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answer this question owing to a very low return of the
questionnaires. In further studies, the questions should be asked
in a personal meeting or telephone call by a certain member of the
team instead of just handing over the questionnaire.
The results presented in this study are in line with data from the
very few randomised studies, with a total of only 264 participants
comparing radiochemotherapy (by using temozolomide, carbo-
platin or methyl-CCNU) with radiotherapy alone in patients with
brain metastases of solid tumours (Ushio et al, 1991; Antonadou
et al, 2002; Guerrieri et al, 2004; Verger et al, 2005), as neither
of these found an influence of the overall survival. In two of
these studies (Ushio et al, 1991; Antonadou et al, 2002), the
objective response rates (96 vs 67% and 74 vs 36%, respectively)
were significantly improved in the patients receiving combined
treatment. However, the response rates mentioned there were
remarkably high.
Two other studies compared the efficacy of chemotherapy alone
with a combination with WBRT (Postmus et al, 2000; Robinet et al,
2001). Postmus et al (2000) used teniposide in 120 patients with
SCLC, and the combined approach resulted in elevated response
rates (57 vs 22%) and a significantly prolonged time-to-progres-
sion (6.5 vs 4 months). Robinet et al (2001), by using cisplatin/
vinorelbine with or without WBRT, found response rates of 33 and
27%, respectively. Again, the OAS was not influenced by either
study.
In summary, on the basis of the results presented here and the
slow recruitment, a continuation of the study did not seem
reasonable. The available data of the only phase III trial concerning
a combined treatment with topotecan and WBRT in patients with
brain metastases due to lung cancer show no advantage for
concurrent radiochemotherapy; however, the recruited number of
patients is too low to exhibit a small advantage of combined
treatment.
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